Q1 2026 · 13F-HR
NEXTBio Capital Management LPholdings as filed
Filed 2026-05-14 · accession 0001172661-26-001957
$215.4M
Reported value
24
Positions
2026-03-31
Period end
The Brief · NEXTBio Capital Management LP · Q1 2026
AI · grounded in 13F
NEXTBio Capital Management LP increased its stake in CMPS by 168.58%. The fund also established a new position in SMMT valued at $1.7M and grew its holding in RYTM by 86.54%. Conversely, the manager trimmed its position in CMPX by 23.86%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $31.9M | 14.8% | 604,534 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $24.2M | 11.2% | 229,619 | Common | SOLE |
| 82024L103 | STTK | SHATTUCK LABS INC | $20.3M | 9.40% | 3,149,907 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $17.8M | 8.28% | 999,967 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $11.2M | 5.19% | 2,021,407 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $11.0M | 5.09% | 126,078 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $10.7M | 4.95% | 183,225 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $10.3M | 4.79% | 82,686 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $8.3M | 3.87% | 426,736 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $7.4M | 3.44% | 1,333,484 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $6.9M | 3.22% | 1,306,800 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $6.8M | 3.18% | 372,856 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $6.6M | 3.08% | 523,619 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.4M | 2.98% | 133,239 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $5.5M | 2.57% | 95,223 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $5.0M | 2.34% | 131,188 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $4.5M | 2.08% | 848,204 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $4.2M | 1.96% | 184,063 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $4.0M | 1.85% | 149,592 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $3.4M | 1.60% | 183,362 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $3.4M | 1.56% | 52,655 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $2.7M | 1.23% | 131,796 | Common | SOLE |
| 86627T108 | SMMT | SUMMIT THERAPEUTICS INC | $1.7M | 0.79% | 89,717 | Common | SOLE |
| 007002207 | ACET | ADICET BIO INC | $1.1M | 0.50% | 157,827 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.